Syndax Pharmaceuticals, Inc

(NASDAQ:SNDX)

Latest On Syndax Pharmaceuticals, Inc (SNDX):

Date/Time Type Description Signal Details
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01N/A
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 02:38 ESTNewsSyndax Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-04 02:40 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 16:35 ESTNewsSyndax Pharmaceuticals: 2023 Is A Pivotal YearN/A
2023-03-01 01:25 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04N/A
2023-02-27 19:50 ESTNewsSyndax Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-12 14:22 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowN/A
2022-12-17 03:56 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at 64th ASH Annual Meeting & ExpositionN/A
2022-12-12 19:48 ESTNewsKura Oncology falls, Syndax gains after Phase 1/2 data for leukemia candidatesN/A
2022-12-10 16:27 ESTNewsSyndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain ProspectN/A
2022-12-07 20:58 ESTNewsSyndax Pharmaceuticals prices $150M offeringN/A
2022-12-07 01:27 ESTNewsSyndax Pharma to sell $150M stock in public offeringN/A
2022-12-05 14:27 ESTNewsSyndax receives breakthrough therapy tag for revumenib to treat acute leukemiaN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call TranscriptN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 08:33 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidanceN/A
2022-11-02 23:19 ESTNewsSyndax Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62N/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 07:37 ESTNewsSyndax Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-13 12:56 ESTNewsKeith Goldan joins Syndax Pharmaceuticals as CFON/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 16:51 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.63N/A
2022-05-09 00:26 ESTNewsSyndax Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 05:11 ESTNewsSyndax Pharmaceuticals: Cash-Rich With 2 Promising DrugsN/A
2022-03-25 00:25 ESTNewsSyndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare ConferenceN/A
2022-03-02 06:49 ESTNewsSyndax appoints former Alnylam executive as new medical chiefN/A
2022-03-02 06:49 ESTNewsSyndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92MN/A
2022-03-02 06:48 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 18:56 ESTNewsSyndax Pharmaceuticals Q4 Earnings PreviewN/A
2022-01-29 06:36 ESTNewsSyndax Pharmaceuticals (SNDX) Investor Presentation - SlideshowN/A
2021-12-23 00:22 ESTNewsSyndax's SNDX-5613 an Orphan Drug in Europe for acute myeloid leukemiaN/A
2021-12-16 14:02 ESTNewsSyndax Pharma raises $75M via stock offeringN/A
2021-12-15 18:28 ESTNewsSyndax Pharmaceuticals drops 6% following underwritten stock offeringN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals EPS misses by $0.35, misses on revenueN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-14 18:13 ESTNewsSyndax Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-04 16:35 ESTNewsSyndax Pharma falls after updating early-stage data for leukemia therapyN/A
2021-10-05 15:59 ESTNewsSyndax Pharma CFO Daphne Karydas to resign to pursue another opportunityN/A
2021-09-28 02:06 ESTNewsIncyte and Syndax in pact for xatilimab targeting immune-related conditionsN/A
2021-08-10 12:01 ESTNewsSyndax Pharmaceuticals EPS beats by $0.28, beats on revenueN/A
2021-08-10 12:00 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 11:59 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 02:04 ESTNewsSyndax Pharmaceuticals: Updated Analysis After Reporting Interim Phase 1 DataN/A
2021-07-22 02:02 ESTNewsCanopy upgraded on economy reopening, Xeris PT cut on acquisition news, and more in analyst actionN/A
2021-07-22 01:35 ESTNewsSyndax shares rise on FDA Fast Track status for leukemia treatment SNDX-5613N/A

About Syndax Pharmaceuticals, Inc (SNDX):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Syndax Pharmaceuticals, Inc
  • Symbol SNDX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 43
  • Fiscal Year EndDecember
  • IPO Date2016-03-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syndax.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 634.74
  • Price/Book (Most Recent Quarter) 4.43
  • Enterprise Value Revenue 542.55
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.19
  • Next Year EPS Estimate -$2.17
  • Next Quarter EPS Estimate -$0.47
  • Operating Margin -4708%
  • Return on Assets -25%
  • Return on Equity -52%
  • Revenue 1.52 million
  • Earnings Per Share -$2.36
  • Revenue Per Share $0.04
  • Gross Profit 1.52 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.16 billion
  • EBITDA -67280000
  • PE Ratio -125.39
  • Analyst Target Price $32.14
  • Book Value Per Share $5.27
View More

Share Statistics

  • Shares Outstanding 48.24 million
  • Shares Float 42.95 million
  • % Held by Insiders 645%
  • % Held by Institutions 78.88%
  • Shares Short 4.93 million
  • Shares Short Prior Month 4.93 million
  • Short Ratio 9.27
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.84
  • 52 Week High $27.12
  • 52 Week Low $8.18
  • 50 Day Moving Average 22.33
  • 200 Day Moving Average 20.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Syndax Pharmaceuticals, Inc (SNDX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Syndax Pharmaceuticals, Inc (SNDX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-08$380000-$0.44-$0.5113.23%
2020-09-302020-11-02$N/A-$0.46-$0.43-6.75%
2020-06-302020-08-06$N/A-$0.42-$0.444.76%
2020-03-312020-05-07$379000-$0.56-$0.53-6.65%
2019-12-312020-03-03$380000-$0.44-$0.43-1.31%
2019-09-302019-11-07$379000-$0.41-$0.4813.92%
2019-06-302019-08-07$379000-$0.47-$0.470.76%
2019-03-312019-05-06$379000-$0.53-$0.554.14%
2018-12-312019-03-07$379000-$0.70-$0.64-9.43%
2018-09-302018-11-05$379000-$0.68-$0.7610.21%
2018-06-302018-08-07$379000-$0.74-$0.8916.94%
2018-03-312018-05-08$379000-$0.79-$0.9517.15%
2017-12-312018-03-05$1.19 million-$0.80-$0.77-3.67%
2017-09-302017-11-07$305000-$0.68-$0.8216.63%
2017-06-302017-08-10$305000-$0.70-$0.8214.83%
2017-03-312017-05-08$305000-$0.71-$0.710.56%
2016-12-312017-03-02$305000-$0.59-$0.7419.79%
2016-09-302016-11-10$305000-$0.84-$0.82-2.78%
2016-06-302016-08-09$305000-$0.47-$0.5412.18%
2016-03-312016-05-16$305000-$0.73-$0.48-52.22%

Syndax Pharmaceuticals, Inc (SNDX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Syndax Pharmaceuticals, Inc (SNDX) Chart:

Syndax Pharmaceuticals, Inc (SNDX) News:

Below you will find a list of latest news for Syndax Pharmaceuticals, Inc (SNDX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Syndax Pharmaceuticals, Inc (SNDX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-172.50CALL0 0399.32TRUE00
2025-04-1750CALL0 0765.78TRUE00
2025-04-177.50CALL0 0370.77TRUE00
2025-04-17102.9CALL0 2250.7TRUE00
2025-04-1712.51.1CALL0 4754.36TRUE00
2025-04-17150.2CALL501 95662.03FALSE-0.05-0.2
2025-04-1717.50.05CALL0 558116.67FALSE00
2025-04-17200.05CALL0 215999.9FALSE00
2025-04-1722.50.2CALL0 63385.41FALSE00
2025-04-17250.19CALL0 16140.39FALSE00
2025-04-17300.05CALL0 84199.22FALSE00
2025-04-17352.7CALL0 1497.94FALSE00
2025-04-17400CALL0 0528.47FALSE00
2025-04-172.50PUT0 00FALSE00
2025-04-1750PUT0 0834.53FALSE00
2025-04-177.50PUT0 0140.96FALSE00
2025-04-17100PUT0 084.92FALSE00
2025-04-1712.50.45PUT0 215862.04FALSE00
2025-04-17151.65PUT0 18398.34TRUE00
2025-04-1717.54PUT0 106104.29TRUE00
2025-04-17204.8PUT0 58188.84TRUE00
2025-04-1722.56.35PUT0 0318.1TRUE00
2025-04-17259.9PUT0 0203.22TRUE00
2025-04-173014PUT0 0196.87TRUE00
2025-04-17350PUT0 0273.78TRUE00
2025-04-17400PUT0 0309.48TRUE00
2025-05-162.50CALL0 0322.7TRUE00
2025-05-1650CALL0 0367.98TRUE00
2025-05-167.50CALL0 097.13TRUE00
2025-05-16100CALL0 086.86TRUE00
2025-05-1612.51.55CALL58 2061.41TRUE1.550
2025-05-16150.45CALL0 25109.59FALSE00
2025-05-1617.50.26CALL0 295.65FALSE00
2025-05-16200CALL0 089.1FALSE00
2025-05-1622.50CALL0 0241.87FALSE00
2025-05-16250CALL0 0260.02FALSE00
2025-05-162.50PUT0 0672.39FALSE00
2025-05-1650PUT0 0308.81FALSE00
2025-05-167.50PUT0 0345.76FALSE00
2025-05-16100PUT0 0126.13FALSE00
2025-05-1612.50.85PUT58 064.09FALSE0.850
2025-05-16150PUT0 053.19TRUE00
2025-05-1617.50PUT0 063.98TRUE00
2025-05-16200PUT0 089.68TRUE00
2025-05-1622.50PUT0 0130.01TRUE00
2025-05-16250PUT0 0127.56TRUE00
2025-07-182.50CALL0 0221.19TRUE00
2025-07-1859.9CALL0 1249.42TRUE00
2025-07-187.50CALL0 051.56TRUE00
2025-07-18104.44CALL0 1762.64TRUE00
2025-07-1812.51.97CALL0 40761.61TRUE00
2025-07-18150.97CALL0 42243.44FALSE00
2025-07-1817.50.48CALL0 110049.63FALSE00
2025-07-18200.17CALL0 46788.08FALSE00
2025-07-1822.50.42CALL0 591.01FALSE00
2025-07-18250.19CALL0 2119.54FALSE00
2025-07-18300.05CALL0 1129.79FALSE00
2025-07-182.50PUT0 0887.02FALSE00
2025-07-1850PUT0 0348.4FALSE00
2025-07-187.50PUT0 0229.06FALSE00
2025-07-18100PUT0 064.49FALSE00
2025-07-1812.51.3PUT0 431261.89FALSE00
2025-07-18153.05PUT0 32058.6TRUE00
2025-07-1817.53.4PUT0 32451.48TRUE00
2025-07-18207.73PUT0 1866.47TRUE00
2025-07-1822.50PUT0 0106.08TRUE00
2025-07-18250PUT0 086.15TRUE00
2025-07-183016.5PUT0 0166.25TRUE00
2025-10-172.50CALL0 0160.2TRUE00
2025-10-1750CALL0 0183.08TRUE00
2025-10-177.50CALL0 074.55TRUE00
2025-10-17100CALL0 063.33TRUE00
2025-10-1712.53.73CALL0 167.34TRUE00
2025-10-17151.95CALL4 427964.1FALSE1.950
2025-10-1717.51.5CALL0 10150.97FALSE00
2025-10-17201.11CALL0 562.11FALSE00
2025-10-1722.50CALL0 063.09FALSE00
2025-10-17250.55CALL0 400063.53FALSE00
2025-10-17300CALL0 083.34FALSE00
2025-10-172.50PUT0 0203.03FALSE00
2025-10-1750PUT0 0121.94FALSE00
2025-10-177.50PUT0 080.59FALSE00
2025-10-17100PUT0 066.24FALSE00
2025-10-1712.50PUT0 047.99FALSE00
2025-10-17153.5PUT0 30266.18TRUE00
2025-10-1717.54.6PUT0 766.9TRUE00
2025-10-17200PUT0 056.92TRUE00
2025-10-1722.50PUT0 062.78TRUE00
2025-10-17250PUT0 088.34TRUE00
2025-10-17300PUT0 0138.99TRUE00
2026-01-162.520.5CALL0 1129.59TRUE00
2026-01-1650CALL0 0156.26TRUE00
2026-01-167.56.75CALL0 2773.58TRUE00
2026-01-16104.61CALL0 2970.21TRUE00
2026-01-1612.56.04CALL0 6167.93TRUE00
2026-01-16152.35CALL0 2566FALSE00
2026-01-1617.54.59CALL0 59463.79FALSE00
2026-01-16201.3CALL0 39563.44FALSE00
2026-01-1622.50.81CALL0 5860.82FALSE00
2026-01-16250.85CALL0 5361.24FALSE00
2026-01-16300.99CALL0 2570.29FALSE00
2026-01-16350.5CALL0 869.02FALSE00
2026-01-162.50PUT0 0127.48FALSE00
2026-01-1650.41PUT0 5224.57FALSE00
2026-01-167.50PUT0 084.39FALSE00
2026-01-16101.17PUT0 559.03FALSE00
2026-01-1612.52.6PUT0 1443.9FALSE00
2026-01-16154.01PUT5 1866.48TRUE0.070.02
2026-01-1617.54.8PUT0 15263.18TRUE00
2026-01-16200PUT0 063.21TRUE00
2026-01-1622.55.1PUT0 666.05TRUE00
2026-01-16250PUT0 055.84TRUE00
2026-01-16300PUT0 070.52TRUE00
2026-01-16350PUT0 0132.67TRUE00

Latest SNDX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST3$15.6
Jun 13, 2022 7:59 PM EST4$15.6
Jun 13, 2022 7:59 PM EST1$15.6
Jun 13, 2022 7:59 PM EST100$15.61
Jun 13, 2022 7:59 PM EST45$15.61

Syndax Pharmaceuticals, Inc (SNDX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2019-09-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1395937/000000000019013216/0000000000-19-013216-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000021545719006549/0000215457-19-006549-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720006818/0000834237-20-006818-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720010194/0000834237-20-010194-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221919000254/0000902219-19-000254-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221920000308/0000902219-20-000308-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266419001816/0000902664-19-001816-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266420000971/0000902664-20-000971-index.htm
2020-11-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000091957420006675/0000919574-20-006675-index.htm
2018-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518001976/0000921895-18-001976-index.htm
2018-11-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518003173/0000921895-18-003173-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189519000467/0000921895-19-000467-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189520000574/0000921895-20-000574-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359419000160/0001013594-19-000160-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359420000127/0001013594-20-000127-index.htm
2018-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/0001140361-18-018005-index.htm
2018-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018007/0001140361-18-018007-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312518197997/0001193125-18-197997-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519034379/0001193125-19-034379-index.htm
2019-03-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519088951/0001193125-19-088951-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312519092679/0001193125-19-092679-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519092701/0001193125-19-092701-index.htm
2019-08-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1395937/000119312519235283/0001193125-19-235283-index.htm
2019-09-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1395937/000119312519239953/0001193125-19-239953-index.htm
2019-09-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519242045/0001193125-19-242045-index.htm
2019-10-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519265254/0001193125-19-265254-index.htm
2020-02-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312520022917/0001193125-20-022917-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312520023646/0001193125-20-023646-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520037637/0001193125-20-037637-index.htm
2020-05-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520139263/0001193125-20-139263-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002680/0001562180-18-002680-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002681/0001562180-18-002681-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002682/0001562180-18-002682-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002683/0001562180-18-002683-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002684/0001562180-18-002684-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002685/0001562180-18-002685-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004047/0001562180-18-004047-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004048/0001562180-18-004048-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004049/0001562180-18-004049-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004050/0001562180-18-004050-index.htm
2018-11-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000852/0001562180-19-000852-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/0001562180-19-000853-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000854/0001562180-19-000854-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000855/0001562180-19-000855-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000856/0001562180-19-000856-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002023/0001562180-19-002023-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003487/0001562180-19-003487-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003488/0001562180-19-003488-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003489/0001562180-19-003489-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003490/0001562180-19-003490-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003491/0001562180-19-003491-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003492/0001562180-19-003492-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003880/0001562180-19-003880-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001228/0001562180-20-001228-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001229/0001562180-20-001229-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001230/0001562180-20-001230-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001231/0001562180-20-001231-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001232/0001562180-20-001232-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001233/0001562180-20-001233-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001234/0001562180-20-001234-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001235/0001562180-20-001235-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001236/0001562180-20-001236-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001237/0001562180-20-001237-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-07-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005102/0001562180-20-005102-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018004520/0001564590-18-004520-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/0001564590-18-004911-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018011784/0001564590-18-011784-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/0001564590-18-012378-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018014349/0001564590-18-014349-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018019907/0001564590-18-019907-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018020483/0001564590-18-020483-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459018020504/0001564590-18-020504-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018023593/0001564590-18-023593-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018026817/0001564590-18-026817-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018026892/0001564590-18-026892-index.htm
2019-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019002676/0001564590-19-002676-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/0001564590-19-006772-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019006777/0001564590-19-006777-index.htm
2019-03-1810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019008313/0001564590-19-008313-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019014263/0001564590-19-014263-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019015972/0001564590-19-015972-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019017318/0001564590-19-017318-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019022241/0001564590-19-022241-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019024625/0001564590-19-024625-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030050/0001564590-19-030050-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019030067/0001564590-19-030067-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030084/0001564590-19-030084-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019036518/0001564590-19-036518-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019041712/0001564590-19-041712-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019041719/0001564590-19-041719-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019045581/0001564590-19-045581-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020004037/0001564590-20-004037-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020005551/0001564590-20-005551-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020008426/0001564590-20-008426-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/0001564590-20-009016-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019694/0001564590-20-019694-index.htm
2020-04-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020019928/0001564590-20-019928-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019941/0001564590-20-019941-index.htm
2020-05-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020020574/0001564590-20-020574-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020020633/0001564590-20-020633-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020022849/0001564590-20-022849-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020022971/0001564590-20-022971-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020031882/0001564590-20-031882-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037719/0001564590-20-037719-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037767/0001564590-20-037767-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020037777/0001564590-20-037777-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020049638/0001564590-20-049638-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020051287/0001564590-20-051287-index.htm
2019-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395937/999999999519002056/9999999995-19-002056-index.htm
2018-11-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999716026189/9999999997-16-026189-index.htm
2018-04-03CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718004150/9999999997-18-004150-index.htm
2018-06-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718006372/9999999997-18-006372-index.htm
2018-08-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718007508/9999999997-18-007508-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718009113/9999999997-18-009113-index.htm
2019-03-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999719002097/9999999997-19-002097-index.htm

Syndax Pharmaceuticals, Inc (SNDX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syndax Pharmaceuticals, Inc (SNDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 645%
Institutional Ownership: 7888%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-03Peter OrdentlichChief Scientific OfficerSell7,500.0015.00112,500.000.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2020-07-06Michael L. MeyersSVP, Chief Medical OfficerBuy3,500.0010,730.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-11-04Michael A MetzgerPresident and COOBuy100,000.007.20720,000.00117,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-09Briggs MorrisonChief Executive OfficerBuy13,200.007.5699,726.0013,200.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2020-02-12Michael A MetzgerPresident and COOBuy15,000.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-11-04Michael A MetzgerPresident and COOSell100,000.0020.312,031,410.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-13Briggs MorrisonChief Executive OfficerBuy7,200.007.2952,516.8020,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2018-10-30Michael L. MeyersSVP, Chief Medical OfficerBuy200.004.79958.002,398.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-10-10Briggs MorrisonChief Executive OfficerBuy11,000.005.4059,400.0031,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-04Briggs MorrisonChief Executive OfficerBuy12,500.008.00100,000.0043,900.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy1,000.004.934,930.007,118.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy104.004.87506.487,222.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2018-04-03Peter OrdentlichChief Scientific OfficerBuy7,500.003.0823,100.007,500.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm